Arrowhead

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

Retrieved on: 
Mittwoch, April 12, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Research, Genetics, Science, Clinical Trials, Molecule, Arrowhead, Rat, Research and development, Central nervous system, Asthma, University, Therapy, Hypertriglyceridemia, File, Leonard M. Miller School of Medicine, CTA, Targeted molecular therapy for neuroblastoma, Brain, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NYU Langone Health, CNS, University of Kansas Medical Center, SOD1, Arrowhead Pharmaceuticals, Patient, Primate, Fatty liver disease, RNA interference, Moyamoya disease, R, Benatar, ALS, Vaccine, Pharmaceutical industry, ASCVD

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m.
  • ET in New York City to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025.
  • The R&D Day will feature presentations by three key opinion leaders: Ira Goldberg, M.D.
  • A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

Retrieved on: 
Dienstag, April 4, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, F3, F2, Week, Liver disease, TAK, Breakthrough therapy, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Trial of the century, Fibrosis, AATD, Arrowhead Pharmaceuticals, Patient, Liver, RNA interference, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, DSM-IV codes, Safety, Pharmaceutical industry, Arrowhead, Takeda

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the first patient has been dosed in Takeda’s (TSE:4502/NYSE:TAK) Phase 3 REDWOOD clinical study of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency associated liver disease (AATD-LD).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the first patient has been dosed in Takeda’s (TSE:4502/NYSE:TAK) Phase 3 REDWOOD clinical study of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency associated liver disease (AATD-LD).
  • The start of this pivotal study triggers a $40 million milestone payment from Takeda to Arrowhead.
  • Z-AAT accumulation is believed to be the cause of progressive liver disease in patients with alpha-1 antitrypsin deficiency (AATD).
  • Reducing production of the mutant Z-AAT protein is expected to halt the progression of liver disease and potentially allow the liver to regenerate and repair.

Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK

Retrieved on: 
Montag, April 3, 2023
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Arrowhead, GSK, NASH, Mutation, Dicarboxylic acid, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Hormone, Alcoholic hepatitis, Arrowhead Pharmaceuticals, Patient, Metabolism, HSD17B13, Fatty liver disease, RNA interference, Cirrhosis, Safety, Pharmaceutical industry, Greater China

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $30 million milestone payment from GSK (LSE/NYSE: GSK) following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA interference (RNAi) therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $30 million milestone payment from GSK (LSE/NYSE: GSK) following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA interference (RNAi) therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH).
  • GSK4532990 is being developed under the November 2021 exclusive license agreement between Arrowhead and GSK.
  • GSK received an exclusive license to develop and commercialize GSK4532990 in all territories except Greater China, which was retained by Arrowhead.
  • GSK is wholly responsible for further clinical development and commercialization, outside of Greater China.

WHAT'S NEW: 2024 LEXUS UX 250H

Retrieved on: 
Mittwoch, April 12, 2023
Caviar, Cloud, HD, Maintenance, Connect, Nintendo Wi-Fi Connection, Macpherson, Hybrid drive, Agility, Aluminium, Electronic stability control, USB, Shock, Human, Android, Multimedia, Lexus, Element, Sale, Tablet, Arrowhead, LED, VSC, ACA, Redline, Amazon Music, Apple, UX, Crosswind, System, Integration, AVS, Lapis lazuli, Glass, Adaptive cruise control, Intelligence, Telescopic sight, Road, Television, Mobile phone, Obsidian

Only offered with a hybrid powertrain in the U.S., the 2024 UX 250h supports Lexus' work towards the realization of a carbon-neutral society.

Key Points: 
  • Only offered with a hybrid powertrain in the U.S., the 2024 UX 250h supports Lexus' work towards the realization of a carbon-neutral society.
  • The 2024 Lexus UX 250h goes on sale this spring.
  • The 2024 Lexus UXh features the Lexus spindle grille, featuring a block-shape mesh pattern with individual elements gradually changing in shape as they radiate out from the central Lexus emblem.
  • Inside the 2024 Lexus UX 250h, essential vehicle functions are grouped around the driver's side of the cabin allowing the driver to maintain a comfortable and natural feel while staying more in touch with the road.

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3

Retrieved on: 
Montag, März 20, 2023
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Arrowhead, Hypertriglyceridemia, Triglyceride, NDA, Fast Track, Merrell Dow Pharmaceuticals Inc. v. Thompson, Trial of the century, Orphan drug, PALISADE, Genetic disorder, Arrowhead Pharmaceuticals, MD, Patient, European, APOC3, RNA interference, FCS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
  • ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union.
  • Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fulfill an unmet medical need.
  • This designation makes Arrowhead eligible for multiple potential benefits including more frequent interactions with FDA, eligibility for accelerated approval and priority review, and rolling review of the new drug application (NDA).

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Retrieved on: 
Dienstag, Februar 28, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Headache, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Safety, Paroxysmal nocturnal hemoglobinuria, PNH, IgA nephropathy, MBA, Immunoglobulin A, Part, Patient, Toxicity, Trial of the century, Arrowhead, Arrowhead Pharmaceuticals, C5, Allergen, Part Two, COVID-19, Pharmacokinetics, RNA, RNA interference, Pharmaceutical industry, Vaccine, C3

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.
  • The company plans to present additional results at an upcoming complement-focused medical meeting.
  • Dosing in Part 2 of the Phase 1/2 study is expected to begin in the first half of 2023.
  • “Substantial unmet medical need remains in the treatment of multiple complement mediated diseases, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and additional renal and hematologic indications, despite the availability of approved complement C5 inhibitors that have significantly improved treatment.

Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Retrieved on: 
Mittwoch, Februar 15, 2023
Health, Genetics, Clinical Trials, Research, Pharmaceutical, Science, NASH, Cirrhosis, Arrowhead Pharmaceuticals, NAFLD, Janssen, Trial of the century, Liver disease, San Diego, University of California, San Diego, Non-alcoholic fatty liver disease, Steatohepatitis, PNPLA3, Safety, Johnson & Johnson, Patient, Liver, RNA, Inflammation, Hepatocellular carcinoma, University, Risk, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Janssen Pharmaceuticals, Chronic liver disease, Plasma, Fatty liver disease, FDA, RNA interference, Prevalence, Pharmacokinetics, Pharmaceutical industry, Arrowhead

PNPLA3 is a unique NASH drug target as the I148M disease associated variant increases the risk of NAFLD, NASH, and hepatocellular carcinoma by 4 to 12-fold for homozygotes.

Key Points: 
  • PNPLA3 is a unique NASH drug target as the I148M disease associated variant increases the risk of NAFLD, NASH, and hepatocellular carcinoma by 4 to 12-fold for homozygotes.
  • We understand that Janssen is undergoing a strategic R&D portfolio review and subsequently advised us of their decision to return full rights to this promising NASH candidate back to Arrowhead,” said Christopher Anzalone, Ph.D., Arrowhead’s president and CEO.
  • Although there are many investigational drugs in clinical study, there are no drugs specifically approved for the treatment of NASH.
  • Up to 30% of those with NAFLD will go on to develop NASH which can progress to liver cirrhosis.

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

Retrieved on: 
Montag, Februar 6, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Moyamoya disease, Trial of the century, NEJM, AHA, SEQUOIA, FCS, PIN, Safety, High-density lipoprotein, Outline, American Heart Association, Patient, Webcast, APOC3, MMP7, Sale, The New England Journal of Medicine, Therapy, Gout, IPF, Takeda, Liver disease, Triglyceride, RNA interference, Idiopathic pulmonary fibrosis, Horizon Therapeutics, Cardiovascular disease, Pharmacokinetics, Hypertriglyceridemia, Arrowhead, Cryptocurrency, Pharmaceutical industry, Amgen

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.
  • The company is hosting a conference call today, February 6, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Donnerstag, Februar 2, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, MBA, Arrowhead Pharmaceuticals, Safety, Patient, RNA, Inflammation, MMP7, Fibrosis, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., IPF, RNA interference, Idiopathic pulmonary fibrosis, Pharmacokinetics, Arrowhead, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
  • “MMP7 is thought to play multiple roles in IPF pathogenesis, including promoting inflammation and aberrant epithelial repair and fibrosis,” said James Hamilton, M.D., MBA, chief of discovery and translational medicine at Arrowhead.
  • “ARO-MMP7 offers a novel approach to potentially address the significant unmet medical need that exists for patients with IPF, who experience progressive decline of lung function, despite currently available therapies.”
    AROMMP7-1001 ( NCT05537025 ) is a Phase 1/2a single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 in up to 56 healthy volunteers and up to 21 patients with IPF.

Give Me Sum Expands and Adds 25 New Locations Across California, Washington, Arizona, Hawaii, and New Mexico

Retrieved on: 
Donnerstag, Februar 16, 2023
Beer, Garlic, DoorDash, Dumpling, German chocolate cake, Wine, Arrowhead, Teahouse, Fast food, Grubhub

BURBANK, Calif., Feb. 16, 2023 /PRNewswire/ -- The delivery-only, Give Me Sum is now making it easier for more diners across the West and Southwest to enjoy the concept's signature dim sum which features traditional selections as well as other craveable small plates, with an expansion of 25 new locations. Following their 2022 launch in Burbank, Fountain Valley and Torrance, Calif., Vancouver and Puyallup, Wash., and Arrowhead and Mesa, Ariz. the dim sum kitchen is responding to the increased demand for its popular and traditional dim sum dishes like its Char Siu Bao, their signature marinated pork steamed bao bun, and perfectly steamed and marinated Dumplings, by adding new locations to California, Arizona and Washington and expanding into Hawaii and New Mexico.

Key Points: 
  • In addition to Give Me Sum's signature dim sum dishes of assorted steamed dumplings and bao buns, the Asian concept also offers non-traditional offerings such as Sum Meaty Fries—perfectly crisp fries served with a choice of protein of either beef or chicken, and either a Teriyaki, or Korean Garlic and Chili sauce.
  • To complement the end of the savory meal, Give Me Sum offers confectionery treats such as green tea or vanilla Mochi and Chocolate Lava Cake.
  • Beer and wine are also available to be ordered as well as non-alcoholic beverages.
  • Give Me Sum's new locations include: